Loading...
XSHE
300171
Market cap1.25bUSD
Jul 10, Last price  
11.68CNY
1D
4.66%
1Q
-21.03%
Jan 2017
-21.56%
IPO
6.76%
Name

Tofflon Science and Technology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300171 chart
P/E
44.35
P/S
1.70
EPS
0.26
Div Yield, %
0.95%
Shrs. gr., 5y
4.17%
Rev. gr., 5y
14.09%
Revenues
5.23b
+4.45%
167,224,594216,248,562308,065,550480,617,136648,865,071821,857,9431,021,120,6201,258,693,7061,555,556,0691,327,836,6011,724,879,1801,916,821,8912,264,004,3282,707,688,1614,192,421,1065,469,426,3615,641,696,4425,010,142,4525,232,922,975
Net income
200m
+3.24%
45,975,21653,385,42675,875,578142,844,836217,402,530233,328,906266,362,883335,411,147386,685,256234,511,456123,097,84770,457,736145,814,768463,493,700827,775,249846,569,062600,237,392194,093,228200,377,381
CFO
731m
-17.01%
32,324,23156,174,914119,108,275118,385,926113,473,861347,375,486338,950,15155,060,521140,664,561107,413,33820,916,734222,035,747446,307,7381,115,814,5391,368,930,358247,153,989-323,940,310880,608,714730,814,415
Dividend
Sep 25, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tofflon Science and Technology Group Co., Ltd., originally established in 1993 as Shanghai Tofflon Science and Technology Co., Ltd. and headquartered in Shanghai, China, serves as a global purveyor of sophisticated equipment for the pharmaceutical and biotechnology sectors. The company's diverse offerings encompass specialized machinery for injectable drug manufacturing, including automated systems for solution preparation, aseptic filling lines tailored for ampoules, vials, syringes, and powders, along with freeze dryers featuring automatic loading capabilities, barrier systems, and plastic packaging machines. Beyond equipment, Tofflon also supplies active pharmaceutical ingredients and provides essential quality control systems such as visual inspection, leak detection, and integrated combination units. Furthermore, Tofflon is a significant provider of bio-process equipment and comprehensive integrated systems. These solutions cover various stages, from medium and buffer preparation to cell/microbial cultivation, harvesting, diafiltration/ultrafiltration (DF/UF), purification, and final filling processes. The company also offers specialized laboratory services for lyophilization of injectables.
IPO date
Feb 01, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT